Biochemical and molecular effects of UCN-01 in combination with 5-fluorodeoxyuridine in A431 human epidermoid cancer cells

Jean L. Grem, Kathleen D. Danenberg, Vivian Kao, Peter V. Danenberg, Diana Nguyen

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Concurrent and pre-exposure of A431 human epidermoid cancer cells to UCN-01, an investigational anticancer drug, with 5-fluoro-2′-deoxyuridine (FdUrd), which targets thymidylate synthase, produced more than additive cytotoxicty, A 24-h exposure to 10 nM FdUrd led to inhibition of TS, a 2.5-fold increase in total thymidylate synthase protein content, profound dTTP depletion and a 6.3-fold increase in the ratio of dATP to dTTP, but did not cause single-strand breaks in DNA. However, FdUrd enhanced UCN-01-associated DNA strand breaks. Concurrent thymidine exposure led to repletion of dTTP pools, and cytoprotection against FdUrd alone and with UCN-01. UCN-01 arrested cells in G1, decreased the percentage of FdUrd-treated cells in S phase and reduced FdUrd-DNA incorporation, suggesting the latter was not important for cytotoxicity. Delayed induction of high molecular mass DNA fragmentation and poly(ADP-ribose) polymerase cleavage was observed with the combination of UCN-01 and FdUrd. These findings suggest that while FdUrd-mediated deoxynucleotide imbalance alone was insufficient to induce apoptosis in this p53-mutant cell line, it magnified UCN-01's effects, most likely by interfering with DNA repair. The clinical evaluation of UCN-01 combined with 5-fluoropyrimidines may be of interest.

Original languageEnglish (US)
Pages (from-to)259-270
Number of pages12
JournalAnti-Cancer Drugs
Volume13
Issue number3
DOIs
StatePublished - May 20 2002

Fingerprint

Floxuridine
Deoxyuridine
Neoplasms
Thymidylate Synthase
Investigational Drugs
Single-Stranded DNA Breaks
DNA Breaks
Cytoprotection
Poly(ADP-ribose) Polymerases
DNA Fragmentation
7-hydroxystaurosporine
S Phase
DNA Repair
Thymidine
Apoptosis
Cell Line
DNA

Keywords

  • 7-Hydroxy-staurospaurine
  • DNA damage
  • Fluoropyrimidines
  • Thymidylate synthase
  • UCN-01

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Cancer Research

Cite this

Biochemical and molecular effects of UCN-01 in combination with 5-fluorodeoxyuridine in A431 human epidermoid cancer cells. / Grem, Jean L.; Danenberg, Kathleen D.; Kao, Vivian; Danenberg, Peter V.; Nguyen, Diana.

In: Anti-Cancer Drugs, Vol. 13, No. 3, 20.05.2002, p. 259-270.

Research output: Contribution to journalArticle

Grem, Jean L. ; Danenberg, Kathleen D. ; Kao, Vivian ; Danenberg, Peter V. ; Nguyen, Diana. / Biochemical and molecular effects of UCN-01 in combination with 5-fluorodeoxyuridine in A431 human epidermoid cancer cells. In: Anti-Cancer Drugs. 2002 ; Vol. 13, No. 3. pp. 259-270.
@article{7adaea08dab549b78af48902183b0343,
title = "Biochemical and molecular effects of UCN-01 in combination with 5-fluorodeoxyuridine in A431 human epidermoid cancer cells",
abstract = "Concurrent and pre-exposure of A431 human epidermoid cancer cells to UCN-01, an investigational anticancer drug, with 5-fluoro-2′-deoxyuridine (FdUrd), which targets thymidylate synthase, produced more than additive cytotoxicty, A 24-h exposure to 10 nM FdUrd led to inhibition of TS, a 2.5-fold increase in total thymidylate synthase protein content, profound dTTP depletion and a 6.3-fold increase in the ratio of dATP to dTTP, but did not cause single-strand breaks in DNA. However, FdUrd enhanced UCN-01-associated DNA strand breaks. Concurrent thymidine exposure led to repletion of dTTP pools, and cytoprotection against FdUrd alone and with UCN-01. UCN-01 arrested cells in G1, decreased the percentage of FdUrd-treated cells in S phase and reduced FdUrd-DNA incorporation, suggesting the latter was not important for cytotoxicity. Delayed induction of high molecular mass DNA fragmentation and poly(ADP-ribose) polymerase cleavage was observed with the combination of UCN-01 and FdUrd. These findings suggest that while FdUrd-mediated deoxynucleotide imbalance alone was insufficient to induce apoptosis in this p53-mutant cell line, it magnified UCN-01's effects, most likely by interfering with DNA repair. The clinical evaluation of UCN-01 combined with 5-fluoropyrimidines may be of interest.",
keywords = "7-Hydroxy-staurospaurine, DNA damage, Fluoropyrimidines, Thymidylate synthase, UCN-01",
author = "Grem, {Jean L.} and Danenberg, {Kathleen D.} and Vivian Kao and Danenberg, {Peter V.} and Diana Nguyen",
year = "2002",
month = "5",
day = "20",
doi = "10.1097/00001813-200203000-00008",
language = "English (US)",
volume = "13",
pages = "259--270",
journal = "Anti-Cancer Drugs",
issn = "0959-4973",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Biochemical and molecular effects of UCN-01 in combination with 5-fluorodeoxyuridine in A431 human epidermoid cancer cells

AU - Grem, Jean L.

AU - Danenberg, Kathleen D.

AU - Kao, Vivian

AU - Danenberg, Peter V.

AU - Nguyen, Diana

PY - 2002/5/20

Y1 - 2002/5/20

N2 - Concurrent and pre-exposure of A431 human epidermoid cancer cells to UCN-01, an investigational anticancer drug, with 5-fluoro-2′-deoxyuridine (FdUrd), which targets thymidylate synthase, produced more than additive cytotoxicty, A 24-h exposure to 10 nM FdUrd led to inhibition of TS, a 2.5-fold increase in total thymidylate synthase protein content, profound dTTP depletion and a 6.3-fold increase in the ratio of dATP to dTTP, but did not cause single-strand breaks in DNA. However, FdUrd enhanced UCN-01-associated DNA strand breaks. Concurrent thymidine exposure led to repletion of dTTP pools, and cytoprotection against FdUrd alone and with UCN-01. UCN-01 arrested cells in G1, decreased the percentage of FdUrd-treated cells in S phase and reduced FdUrd-DNA incorporation, suggesting the latter was not important for cytotoxicity. Delayed induction of high molecular mass DNA fragmentation and poly(ADP-ribose) polymerase cleavage was observed with the combination of UCN-01 and FdUrd. These findings suggest that while FdUrd-mediated deoxynucleotide imbalance alone was insufficient to induce apoptosis in this p53-mutant cell line, it magnified UCN-01's effects, most likely by interfering with DNA repair. The clinical evaluation of UCN-01 combined with 5-fluoropyrimidines may be of interest.

AB - Concurrent and pre-exposure of A431 human epidermoid cancer cells to UCN-01, an investigational anticancer drug, with 5-fluoro-2′-deoxyuridine (FdUrd), which targets thymidylate synthase, produced more than additive cytotoxicty, A 24-h exposure to 10 nM FdUrd led to inhibition of TS, a 2.5-fold increase in total thymidylate synthase protein content, profound dTTP depletion and a 6.3-fold increase in the ratio of dATP to dTTP, but did not cause single-strand breaks in DNA. However, FdUrd enhanced UCN-01-associated DNA strand breaks. Concurrent thymidine exposure led to repletion of dTTP pools, and cytoprotection against FdUrd alone and with UCN-01. UCN-01 arrested cells in G1, decreased the percentage of FdUrd-treated cells in S phase and reduced FdUrd-DNA incorporation, suggesting the latter was not important for cytotoxicity. Delayed induction of high molecular mass DNA fragmentation and poly(ADP-ribose) polymerase cleavage was observed with the combination of UCN-01 and FdUrd. These findings suggest that while FdUrd-mediated deoxynucleotide imbalance alone was insufficient to induce apoptosis in this p53-mutant cell line, it magnified UCN-01's effects, most likely by interfering with DNA repair. The clinical evaluation of UCN-01 combined with 5-fluoropyrimidines may be of interest.

KW - 7-Hydroxy-staurospaurine

KW - DNA damage

KW - Fluoropyrimidines

KW - Thymidylate synthase

KW - UCN-01

UR - http://www.scopus.com/inward/record.url?scp=0036245507&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036245507&partnerID=8YFLogxK

U2 - 10.1097/00001813-200203000-00008

DO - 10.1097/00001813-200203000-00008

M3 - Article

C2 - 11984070

AN - SCOPUS:0036245507

VL - 13

SP - 259

EP - 270

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

IS - 3

ER -